Heavy menstrual bleeding is prolonged (>7 days) or excessive (>10 mL) uterine bleeding occurring at regular intervals over several menstrual cycles.
It is menstrual blood loss that is excessive and interferes with patient's physical, emotional, social and quality of life.
It is also referred to as menorrhagia or hypermenorrhea.
It is a common problem in women of reproductive age that usually causes anemia.
Uterine fibroids and polyps are the most common pathology identified.

Heavy Menstrual Bleeding Drug Information

Drug Information

Indication: Contraception.

Indication: Mild to moderate pain, rheumatic disorders, dysmenorrhoea, menorrhagia.

Indication: Symptomatic relief of RA eg, Still's disease, OA & pain eg, muscular, traumatic & dental pain, headach...

Indication: Relief of mild to moderate pain including muscular, traumatic, dental pain, headache, post-op, postpartum pain...

Indication: Ankylosing spondylitis, OA, RA & acute gout. Mild to moderate pain eg, migraine, primary dysmenorrhoea, ac...

Indication: Musculoskeletal & joint disorders eg, ankylosing spondylitis, OA & RA. Mild to moderate pain eg, dysme...

Indication: Relief of pain & inflammation in rheumatic disorders, acute gout & other musculoskeletal disorders.

Indication: Amenorrhea, abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology eg, submuc...

Indication: Mild to moderate pain, primary dysmenorrhoea. RA, OA, ankylosing spondylitis, tendinitis, bursitis, acute gout...

Indication: Relief of mild to moderate pain. Primary dysmenorrhea. Relief/prophylaxis of migraine headache. Symptomatic tr...

2  /  4
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
Adding the CDK4/6 inhibitor abemaciclib to an endocrine therapy of fulvestrant extends overall survival (OS) compared with fulvestrant alone in East Asian patients with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC) who have progressed on prior endocrine therapy, consistent with results from the overall population, updated analysis of the global, phase III MONARCH 2 study has shown.
01 Sep 2020
Acute diarrhoea is the second leading cause of deathin children aged younger than 5 years, accounting forapproximately 1.9 million deaths worldwide each year;however, diarrhoea is a preventable and treatable condition.In Malaysia, acute gastroenteritis accounts for about 1.3%of all deaths in children aged younger than 5 years annually.Diarrhoea is defined as the passage of three or more looseor watery stools within 24 hours, and it may be clinicallycategorised as either acute watery diarrhoea (AWD), acutebloody diarrhoea, persistent diarrhoea or diarrhoea withsevere malnutrition.